Journal of Pathology and Translational Medicine

Original Articles

Immunohistochemical Classification of Primary and Secondary Glioblastomas: Kyu Sang Lee, Gheeyoung Choe, Kyung Han Nam, An Na Seo, Sumi Yun, Kyung Ju Kim, Hwa Jin Cho, Sung Hye Park; Korean J Pathol. 2013;47(6):541-548. Published online December 24, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.6.541

7,048 View
51 Download
16 Crossref

Background

Glioblastomas may develop de novo (primary glioblastomas, P-GBLs) or through progression from lower-grade astrocytomas (secondary glioblastomas, S-GBLs). The aim of this study was to compare the immunohistochemical classification of glioblastomas with clinically determined P-GBLs and S-GBLs to identify the best combination of antibodies for immunohistochemical classification.

Methods

We evaluated the immunohistochemical expression of epidermal growth factor receptor (EGFR), p53, and isocitrate dehydrogenase 1 (IDH-1) in 150 glioblastoma cases.

Results

According to clinical history, the glioblastomas analyzed in this study consisted of 146 P-GBLs and 4 S-GBLs. Immunohistochemical expression of EGFR, p53, and IDH-1 was observed in 62.6%, 49.3%, and 11.1%, respectively. Immunohistochemical profiles of EGFR(+)/p53(-), IDH-1(-)/EGFR(+)/p53(-), and EGFR(-)/p53(+) were noted in 41.3%, 40.2%, and 28.7%, respectively. Expression of IDH-1 and EGFR(-)/p53(+) was positively correlated with young age. The typical immunohistochemical features of S-GBLs comprised IDH-1(+)/EGFR(-)/p53(+), and were noted in 3.6% of clinically P-GBLs. The combination of IDH-1(-) or EGFR(+) was the best set of immunohistochemical stains for identifying P-GBLs, whereas the combination of IDH-1(+) and EGFR(-) was best for identifying S-GBLs.

Conclusions

We recommend a combination of IDH-1 and EGFR for immunohistochemical classification of glioblastomas. We expect our results to be useful for determining treatment strategies for glioblastoma patients.

Citations

Citations to this article as recorded by

Cutaneous Melanoma and Glioblastoma Multiforme Association—Case Presentation and Literature Review
Olguța Anca Orzan, Călin Giurcăneanu, Bogdan Dima, Monica Beatrice Dima, Ana Ion, Beatrice Bălăceanu, Cornelia Nițipir, Irina Tudose, Cătălina Andreea Nicolae, Alexandra Maria Dorobanțu
Diagnostics.2023; 13(6): 1046. CrossRef
Primary Extra-axial Glioblastoma: Case Report and Literature Review
Baraa Dabboucy, Philippe Younes, Abdallah Rahbani, Elie Fahed, Gérard Abadjian
Arquivos Brasileiros de Neurocirurgia: Brazilian Neurosurgery.2021; 40(04): e368. CrossRef
TERT Promoter Mutation in Adult Glioblastomas: It's Correlation with Other Relevant Molecular Markers
Mukesh Barange, Sridhar Epari, Mamta Gurav, Omshree Shetty, Ayushi Sahay, Prakash Shetty, Jayantsastri Goda, Aliasagar Moyiadi, Tejpal Gupta, Rakesh Jalali
Neurology India.2021; 69(1): 126. CrossRef
Immunohistochemical characterisation and histopathology of astrocytic neoplasms at a tertiary Nigerian hospital
Michael Nweke, Gabriel Ogun, Amos Adeleye, Clement A. Okolo, Adekunle Adesina
International Journal of Clinical Practice.2021;[Epub] CrossRef
Cytotoxic Effects of Blue Scorpion Venom (Rhopalurus junceus) in a Glioblastoma Cell Line Model
Laura A. Lozano-Trujillo, Diana K. Garzón-Perdomo, Andrea C.R. Vargas, Lina M. de los Reyes, Marco F. Avila-Rodriguez, Olivia T.G. Gay, Liliana F. Turner
Current Pharmaceutical Biotechnology.2021; 22(5): 636. CrossRef
Molecular Subgroups of Glioblastoma– an Assessment by Immunohistochemical Markers
Ádám Nagy, Ferenc Garzuly, Gergely Padányi, Iván Szűcs, Ádám Feldmann, Balázs Murnyák, Tibor Hortobágyi, Bernadette Kálmán
Pathology & Oncology Research.2019; 25(1): 21. CrossRef
Proteomic Advances in Glial Tumors through Mass Spectrometry Approaches
Radu Pirlog, Sergiu Susman, Cristina Adela Iuga, Stefan Ioan Florian
Medicina.2019; 55(8): 412. CrossRef
Isocitrate dehydrogenase 1 mutant glioblastomas demonstrate a decreased rate of pseudoprogression: a multi-institutional experience
Homan Mohammadi, Kevin Shiue, G Daniel Grass, Vivek Verma, Kay Engellandt, Dirk Daubner, Gabriele Schackert, Mercia J Gondim, Dibson Gondim, Alexander O Vortmeyer, Aaron P Kamer, William Jin, Timothy J Robinson, Gordon Watson, Hsiang-Hsuan M Yu, Tim Laute
Neuro-Oncology Practice.2019;[Epub] CrossRef
Calvarium mass as the first presentation of glioblastoma multiforme: A very rare manifestation of high-grade glioma
S. Taghipour Zahir, M. Mortaz, M. Baghi Yazdi, N. Sefidrokh Sharahjin, M. Shabani
Neurochirurgie.2018; 64(1): 76. CrossRef
Malignant Gliomas as Second Neoplasms in Pediatric Cancer Survivors: Neuropathological Study
Ewa Izycka-Swieszewska, Ewa Bien, Joanna Stefanowicz, Edyta Szurowska, Ewa Szutowicz-Zielinska, Magdalena Koczkowska, Dawid Sigorski, Wojciech Kloc, Wojciech Rogowski, Elzbieta Adamkiewicz-Drozynska
BioMed Research International.2018; 2018: 1. CrossRef
Prognostic significance of mutant IDH1, CD133, and β-catenin immunohistochemical expression in glioblastoma multiforme
Azza Abdel-Aziz, Mie A. Mohamed, Dina Abdallah, Fatma M.F. Akl, Ghada E. Eladawy, Ahmed N. Taha, Hossam Shata
Egyptian Journal of Pathology.2018; 38(1): 27. CrossRef
On glioblastoma and the search for a cure: where do we stand?
John Bianco, Chiara Bastiancich, Aleksander Jankovski, Anne des Rieux, Véronique Préat, Fabienne Danhier
Cellular and Molecular Life Sciences.2017; 74(13): 2451. CrossRef
Development of Glioblastoma after Treatment of Brain Abscess
Hiroaki Matsumoto, Hiroaki Minami, Shogo Tominaga, Yasuhisa Yoshida
World Neurosurgery.2016; 88: 686.e19. CrossRef
Clinical, immunohistochemical, and molecular genetic prognostic factors in adult patients with glioblastoma
N. V. Lobanova, L. V. Shishkina, M. V. Ryzhova, G. L. Kobyakov, R. V. Sycheva, S. A. Burov, A. V. Lukyanov, Zh. R. Omarova
Arkhiv patologii.2016; 78(4): 10. CrossRef
Concordance analysis and diagnostic test accuracy review of IDH1 immunohistochemistry in glioblastoma
Jung-Soo Pyo, Nae Yu Kim, Roy Hyun Jai Kim, Guhyun Kang
Brain Tumor Pathology.2016; 33(4): 248. CrossRef
Methyl Guanine Methyl Transferase Methylation Status and Epidermal Growth Factor Receptor expression in a cohort of Egyptian glioblastoma patients
Soheir M. Hamam, Bassma M. El Sabaa, Iman M. Talaat, Rasha A. Nassra, Doaa A. Abdelmonsif
Egyptian Journal of Pathology.2016; 36(2): 282. CrossRef

Expression of p53 and Vascular Endothelial Growth Factor mRNA in Angiogenesis of Non-Small Cell Lung Carcinoma.: Jun Seog Kim, Tae In Park, Myoung Hoon Lee, Eun Kyoung Kwak, Ji Young Park, Jung Sik Kwak, Jong Min Chae; Korean J Pathol. 2003;37(1):35-40.

1,588 View
11 Download

Abstract PDF: BACKGROUND
Angiogenesis is one of the most important factors in the progression and me-tastasis of malignancies. Angiogenesis is a multistep process requiring the interaction of numerous factors able to stimulate the growth and development of new vessels. But, understanding of the mechanism involved in VEGF expression is unclear.
METHODS
Expressions of p53 and VEGF, and neovasculiarization were examined in 19 cases of surgically resected non-small cell carcinoma of the lung by the immunohistochemical staining. Furthermore, VEGF mRNA expressions were quantified in all cases using the real-time quantitative RT-PCR. These results were compared with clinicopathologic parameters such as histologic grade and stage.
RESULTS
Tumors with high aberrant p53 expressions showed significantly higher VEGF mRNA ex-pressions and microvessel counts than those with low p53 expressions. Expressions of p53 as well as VEGF and micovessel counts were closely associated with the tumor stage, but not with the histologic grade and other clinical parameters.
CONCLUSIONS
These results suggest that aberrant p53 expression may play a role in the regulation of VEGF expression and may be involved in controlling angiogenesis in non-small cell carcinoma of the lung.

PTEN and p53 Mutations in Endometrial Carcinomas.: Jae Sung Choi, Kwang Sun Suh, Heung Tae Noh, Yun Ee Rhee, Sun Young Na, Hye Kyung Lee; Korean J Pathol. 2005;39(1):1-8.

1,810 View
19 Download

Abstract PDF: BACKGROUND
Endometrial carcinomas are pathogenetically classified into two major types; endometrioid carcinoma (EC) and serous carcinoma (SC). The most frequently altered gene in EC is the PTEN tumor suppressor gene (TSG). SC is usually associated with mutations in the p53 TSG.
METHODS
To further determine the role of PTEN and p53 mutation in endometrial carcinogenesis, the analysis of 33 endometrial carcinomas, including 28 ECs and 5 SCs, for loss of heterozygosity (LOH) on 10q23 and for mutation in all 9 coding exons of PTEN and the 5-8 exons of p53, using SSCP-PCR methods was carried out.
RESULTS
LOH was detected in at least one marker in 12 (54.5%) of 22 ECs, but in only one (20.0%) of 5 SCs. Somatic PTEN mutations were detected in 10 (35.7%) of 28 ECs. PTEN was altered in 67.9% of ECs and in 20.0% of SCs, including those with 10q23 LOH. No PTEN mutations were found among the SCs. Somatic p53 mutations were detected in 2 (7.1%) of 28 ECs and 3 (60.0%) of 5 SCs.
CONCLUSIONS
PTEN gene alterations contribute to the pathogenesis of an endometrioid subtype of endometrial carcinoma, but not to the serous type. In contrast, p53 plays an important role in the pathogenesis of SCs.

First
Prev
Page of 1
Next
Last

Search